| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Former 10% Owner | 10% Owner
3 companies
Column Group II, LP last filed a Form 4 in December 2024, as 10% Owner at RCUS. The filings on record cover 3 companies.
Our model assigns Column Group II, LP a strong insider score of 83/100, based on 14 past trades. Over a 12-month horizon, all 14 of those trades were profitable, with an average 12-month return of +34.6%.
At the last filing, the largest reported position was 470,427 shares of RCUS.
Column Group II, LP has 21 Form 4 filings on record from March 2018 to December 2024, across 3 companies: Former 10% Owner at RAPT Therapeutics (RAPT), 2019–2024; 10% Owner at Oric Pharmaceuticals (ORIC), 2020–2021; 10% Owner at Arcus Biosciences (RCUS), 2018.
The 112 reported transactions were 48 open-market sales, 29 other transactions, 17 open-market purchases and 14 conversions, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 7 purchases worth about $34.9M and 7 sales worth about $44.7M.
The largest open-market purchase was 1,250,000 shares of RAPT at an average $10.67 on May 10, 2022, about $13.3M. Twelve months later RAPT was up 77%.
The largest open-market sale was 608,000 shares of RAPT at an average $30.85 on September 22, 2020, about $18.8M.
Shares as reported in the last Form 4 for each company; the most recent is from December 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 25, 2022 | RAPT Rapt Therapeutics, Inc. | 10% Owner | Buy | 1,900 | $12.45 | $23,664.31 | +4.7% | +93.5% | +47.0% | |
| May 25, 2022 | RAPT Rapt Therapeutics, Inc. | 10% Owner | Buy | 1,900 | $12.45 | $23,664.31 | +4.7% | +93.5% | +47.0% | |
| May 24, 2022 | RAPT Rapt Therapeutics, Inc. | 10% Owner | Buy | 26,550 | $12.19 | $323,745.09 | +170.5% | +110.2% | +67.4% | |
| May 24, 2022 | RAPT Rapt Therapeutics, Inc. | 10% Owner | Buy | 26,550 | $12.19 | $323,745.09 | +170.5% | +110.2% | +67.4% | |
| May 10, 2022 | RAPT Rapt Therapeutics, Inc. | 10% Owner | Buy | 1,250,000 | $10.67 | $13,339,375.00 | -103.4% | +95.7% | +77.4% | |
| May 10, 2022 | RAPT Rapt Therapeutics, Inc. | 10% Owner | Buy | 1,250,000 | $10.67 | $13,339,375.00 | -103.4% | +95.7% | +77.4% | |
| Sep 27, 2021 | RAPT Rapt Therapeutics, Inc. | 10% Owner | Sale+OE | 9,239 | $34.57 | $319,397.39 | - | +5.9% | -30.8% | |
| Sep 15, 2021 | RAPT Rapt Therapeutics, Inc. | 10% Owner | Sell | 181,211 | $37.01 | $6,707,218.01 | -100% | -18.6% | -29.2% | |
| Sep 13, 2021 | RAPT Rapt Therapeutics, Inc. | 10% Owner | Sell | 36,055 | $35.22 | $1,269,949.80 | -49.6% | -9.2% | -27.1% | |
| Sep 2, 2021 | RAPT Rapt Therapeutics, Inc. | 10% Owner | Sell | 68,850 | $35.34 | $2,433,143.22 | -100% | -13.3% | -26.3% |